Filing Flows › AstraZeneca (AZN) › Q3 2026
AstraZeneca (AZN) Q3 2026 earnings results (third quarter 2026)
6-K filed Oct 30, 2026
AstraZeneca (AZN) reported revenue of $16.2B for the third quarter 2026 (Q3 2026), +7% from a year earlier. Operating margin was 27.1%, net earnings $3.1B (19.2% of revenue).
AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.2B | — | +7% |
| Gross profit | $13.3B | — | +7% |
| Operating profit | $4.4B | — | +22% |
| Net earnings | $3.1B | — | +23% |
| Operating cash flow | $5.8B | — | — |
| Free cash flow | $5.1B | — | — |
What changed
Revenue was $16.2B in Q3 2026, up 7% year over year. Oncology was the largest line at 44% of revenue.
Gross margin was 81.8%, up 0.3 points from a year earlier. Operating profit was $4.4B, a 27.1% margin (up 3.5 points year over year). Of the extra revenue versus a year earlier, 79% reached operating profit, above the 24% margin then. Operating expenses grew 1% against revenue growth of 7%. Net earnings were $3.1B, up 23% year over year. The effective tax rate was 21.3%.
Operating cash flow was $5.8B, 185% of net earnings. Working capital and other items added $2.6B. Capital expenditures of $0.68B left free cash flow of $5.1B.
Questions
What was AstraZeneca's revenue in the third quarter 2026?
AstraZeneca (AZN) reported revenue of $16.2B for the third quarter 2026 (Q3 2026), +7% from a year earlier.
Was AstraZeneca profitable in the third quarter 2026?
Operating profit was $4.4B (27.1% of revenue) and net earnings $3.1B.
Source: AstraZeneca 6-K on SEC EDGAR.